These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1725195)

  • 21. Angiotensin receptor blockers: current status and future prospects.
    Kumar S; Ram CV
    Indian Heart J; 2007; 59(6):443-53. PubMed ID: 19151457
    [No Abstract]   [Full Text] [Related]  

  • 22. The use of ACE inhibitor in cardiovascular disease.
    Nasution SA
    Acta Med Indones; 2006; 38(1):60-4. PubMed ID: 16479034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases.
    Liao Y; Husain A
    Can J Cardiol; 1995 Aug; 11 Suppl F():13F-19F. PubMed ID: 7664213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current indications for ACE inhibitors and HOPE for the future.
    Burch S; Ou N
    Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Symposium on Converting Enzyme Inhibitors in Cardiovascular Diseases. Sao Paulo, 2 September 1989].
    Arq Bras Cardiol; 1990 Aug; 55 Suppl A():A1-22. PubMed ID: 1982701
    [No Abstract]   [Full Text] [Related]  

  • 26. Antihypertensive strategy using angiotensin converting inhibitors. Official satellite symposium to the 12th scientific meeting of the International Society of Hypertension. Kyoto, Japan, May 27, 1988.
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S1-80. PubMed ID: 2474094
    [No Abstract]   [Full Text] [Related]  

  • 27. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE inhibitors and the arterial wall. Introduction.
    Frishman WH
    Postgrad Med; 2000 Oct; 108(5 Suppl):3. PubMed ID: 19667534
    [No Abstract]   [Full Text] [Related]  

  • 29. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of ACE inhibitor therapy in treating cardiovascular disease.
    Flint L
    Nurs Times; 2004 Mar 23-29; 100(12):34-7. PubMed ID: 15067910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiovascular protection using ACE inhibitors (captopril). Additional benefits for patients with hypertension and coronary insufficiency. Abstracts from the International Symposium on ACE-Inhibition London, 14-17 February 1989].
    Fortschr Med Suppl; 1989; 65():1-18. PubMed ID: 2670720
    [No Abstract]   [Full Text] [Related]  

  • 34. What to treat? The structural basis for renal and vascular complications and hypertension, and the role of angiotensin converting enzyme inhibition. Symposium, 26th meeting of the European Association for the Study of Diabetes. Dublin, Ireland, 10 September 1991.
    J Hypertens Suppl; 1992 Apr; 10(1):S1-53. PubMed ID: 1619498
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential.
    Manikandan A; Moharil P; Sathishkumar M; Muñoz-Garay C; Sivakumar A
    Eur J Med Chem; 2017 Dec; 141():417-426. PubMed ID: 29032034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].
    Scheen AJ
    Rev Med Liege; 1999 Oct; 54(10):835-6. PubMed ID: 10605322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The clinical use of angiotensin converting enzyme inhibitors].
    Fyhrquist F
    Duodecim; 1986; 102(22):1709-16. PubMed ID: 3026771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.